ALK and non-small cell lung carcinoma: In a more recently published phase III randomized trial, ALINA, which evaluated the use of adjuvant alectinib in patients with resected stage IB–IIIA NSCLC with ALK-positive mutations, 16% of patients met study inclusion criteria and were eligible for treatment with adjuvant alectinib (or placebo) [21].